Research
Hormonal
Lorcaserin extended release (XR) 20 mg once daily is bioequivalent to lorcaserin immediate release (IR) 10 mg twice daily in terms of total exposure (AUC), offering a convenience advantage with potentially lower peak concentrations (Cmax).
If you are prescribed lorcaserin XR, take 20 mg once a day, with or without food. This formulation is designed to provide the same total amount of medication as the older twice-daily version but with a lower peak concentration, which may reduce side effects like headaches. Consistency is key; take it at the same time each day.
GoodSupportsHIGH confidence
The authors concluded that the AUC (IR 1328 h⋅ng/mL; XR 1235 h⋅ng/mL) and mean Cmax (IR, 80.1 ng/mL; XR, 73.9 ng/mL) were within statistical boundaries when using geometric mean ratio analysis (90% CI) and could be considered bioequivalent.
Why this rating
Based on pivotal bioequivalence studies and large Phase III trials.
Source
Challenging obesity, diabetes, and addiction: the potential of lorcaserin extended release
Ryan T. Hurt et al. · Diabetes Metabolic Syndrome and Obesity · 2018
DOI 10.2147/dmso.s126855
narrative_reviewCited 9×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Lorcaserin IR and XR promote weight loss and improve glycemic control in overweight or obese patients with type 2 diabetes when used as an adjunct to lifestyle modifications.Good
- Lorcaserin IR (twice daily) improves smoking cessation rates and prevents post-cessation weight gain in overweight or obese smokers compared to placebo.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →